Rezolute, Inc. (RZLT)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$3.860.00%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Rezolute, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	1.17M
EPS	—	-0.173
Annual ending 2027-06-30
Revenue	—	2.56M
EPS	—	-0.706
Annual ending 2028-06-30
Revenue	—	54.09M
EPS	—	-0.518

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
reduce EPS losses toward zero	A primary condition in Rezolute, Inc.'s published investment case. The stated target is EPS loss improves to better than -$0.63 in FY27.	Intact	EPS loss worsens beyond -$0.63 in FY27	Diluted EPS: $-0.20 per share FY2026-Q4; GAAP. Published target: EPS loss improves to better than -$0.63 in FY27. Target period is not explicitly aligned with this observation. Source published Sep 24, 2026-0.2 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q4 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q4. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
management stability and insider confidence	Rezolute is developing therapies for rare diseases with insider buying showing confidence.	Intact	significant insider selling or management instability	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
grow revenue from rare disease therapies	Rezolute is developing therapies for rare diseases with insider buying showing confidence.	Intact	revenue falls below $2.3 million in FY27	Revenue: $0 FY2026-Q4; GAAP. Published target: revenue reaches at least $2.3 million in FY27. Target period is not explicitly aligned with this observation. Source published Sep 24, 20260 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q4 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q4. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-06-30 · fmp

FY2028 EPS$-0.52

$-0.33 → $-0.52 · observed estimates

FY2028 revenue$0.05B

$0.07B → $0.05B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.33	$66,098,142	7 / 7
2026-07-25	$-0.33	$66,098,142	7 / 7
2026-07-26	$-0.33	$66,098,142	7 / 7
2026-07-27	$-0.33	$66,098,142	7 / 7
2026-07-28	$-0.33	$66,098,142	7 / 7
2026-07-29	$-0.33	$66,098,142	7 / 7
2026-07-30	$-0.33	$66,098,142	7 / 7
2026-07-31	$-0.33	$66,098,142	7 / 7
2026-08-01	$-0.33	$66,098,142	7 / 7
2026-08-02	$-0.33	$66,098,142	7 / 7
2026-08-03	$-0.33	$66,098,142	7 / 7
2026-08-04	$-0.33	$66,098,142	7 / 7
2026-08-05	$-0.33	$66,098,142	7 / 7
2026-08-06	$-0.33	$66,098,142	7 / 7
2026-08-08	$-0.33	$66,098,142	7 / 7
2026-08-09	$-0.33	$66,098,142	7 / 7
2026-08-10	$-0.33	$66,098,142	7 / 7
2026-08-12	$-0.33	$66,098,142	7 / 7
2026-08-13	$-0.33	$66,098,142	7 / 7
2026-08-14	$-0.33	$66,098,142	7 / 7
2026-08-15	$-0.33	$66,098,142	7 / 7
2026-08-16	$-0.33	$66,098,142	7 / 7
2026-08-17	$-0.33	$66,098,142	7 / 7
2026-08-18	$-0.33	$66,098,142	7 / 7
2026-08-19	$-0.33	$66,098,142	7 / 7
2026-08-20	$-0.33	$66,098,142	7 / 7
2026-08-21	$-0.33	$66,098,142	7 / 7
2026-08-22	$-0.33	$66,098,142	7 / 7
2026-08-23	$-0.33	$66,098,142	7 / 7
2026-08-24	$-0.33	$66,098,142	7 / 7
2026-08-25	$-0.33	$66,098,142	7 / 7
2026-08-26	$-0.33	$66,098,142	7 / 7
2026-08-27	$-0.33	$66,098,142	7 / 7
2026-08-28	$-0.33	$66,098,142	7 / 7
2026-08-29	$-0.33	$66,098,142	7 / 7
2026-08-30	$-0.33	$66,098,142	7 / 7
2026-08-31	$-0.33	$66,098,142	7 / 7
2026-09-01	$-0.33	$66,098,142	7 / 7
2026-09-02	$-0.33	$66,098,142	7 / 7
2026-09-03	$-0.33	$66,098,142	7 / 7
2026-09-04	$-0.33	$66,098,142	7 / 7
2026-09-05	$-0.33	$66,098,142	7 / 7
2026-09-06	$-0.33	$66,098,142	7 / 7
2026-09-07	$-0.33	$66,098,142	7 / 7
2026-09-08	$-0.33	$66,098,142	7 / 7
2026-09-09	$-0.33	$66,098,142	7 / 7
2026-09-10	$-0.22	$75,156,000	7 / 7
2026-09-11	$-0.22	$75,156,000	7 / 7
2026-09-12	$-0.22	$75,156,000	7 / 7
2026-09-13	$-0.33	$66,098,142	7 / 7
2026-09-14	$-0.33	$66,098,142	7 / 7
2026-09-15	$-0.33	$66,098,142	7 / 7
2026-09-16	$-0.33	$66,098,142	7 / 7
2026-09-17	$-0.33	$66,098,142	7 / 7
2026-09-18	$-0.33	$66,098,142	7 / 7
2026-09-19	$-0.33	$66,098,142	7 / 7
2026-09-20	$-0.33	$66,098,142	7 / 7
2026-09-21	$-0.33	$66,098,142	7 / 7
2026-09-22	$-0.33	$66,098,142	7 / 7
2026-09-23	$-0.33	$66,098,142	7 / 7
2026-09-24	$-0.33	$66,098,142	7 / 7
2026-09-25	$-0.32	$96,181,000	6 / 6
2026-09-26	$-0.41	$72,839,400	5 / 5
2026-09-27	$-0.41	$72,839,400	5 / 5
2026-09-28	$-0.41	$72,839,400	5 / 5
2026-09-29	$-0.41	$72,839,400	5 / 5
2026-09-30	$-0.45	$64,542,429	5 / 6
2026-10-01	$-0.45	$64,548,142	5 / 6
2026-10-02	$-0.52	$56,792,125	6 / 7
2026-10-03	$-0.52	$56,792,125	6 / 7
2026-10-04	$-0.52	$56,792,125	6 / 7
2026-10-05	$-0.52	$56,792,125	6 / 7
2026-10-06	$-0.52	$56,792,125	6 / 7
2026-10-07	$-0.51	$57,106,889	6 / 7
2026-10-08	$-0.51	$57,258,000	6 / 7
2026-10-09	$-0.51	$57,258,000	6 / 7
2026-10-10	$-0.51	$57,258,000	6 / 7
2026-10-11	$-0.51	$57,258,000	6 / 7
2026-10-12	$-0.51	$57,258,000	6 / 7
2026-10-13	$-0.51	$57,258,000	6 / 7
2026-10-14	$-0.51	$57,258,000	6 / 7
2026-10-15	$-0.51	$57,258,000	6 / 7
2026-10-16	$-0.51	$57,258,000	6 / 6
2026-10-17	$-0.51	$57,258,000	6 / 6
2026-10-18	$-0.52	$54,094,000	6 / 7
2026-10-19	$-0.52	$54,094,000	6 / 7
2026-10-20	$-0.52	$54,094,000	6 / 7
2026-10-21	$-0.52	$54,094,000	6 / 7
2026-10-22	$-0.52	$54,094,000	6 / 7
2026-10-23	$-0.52	$54,094,000	6 / 7
2026-10-24	$-0.52	$54,094,000	6 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	7	3
2026-06-01	8	3
2026-07-01	8	2
2026-08-01	8	2
2026-09-01	10	2
2026-10-01	11	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 11 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

2 upgrades0 downgrades3 maintains

Recent actions · Sep 25–Oct 24 · 5 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Lake StreetOct 6 · prior Sep 30

$9.00 → $12.00+33.3%

Craig-HallumSep 29

$7.00New observation · no comparable prior

H.C. WainwrightSep 25

$10.00New observation · no comparable prior

$0$6.60$13.20

1 raises · 0 cuts · 0 unchanged · 2 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

reduce EPS losses toward zeroDiluted EPS: $-0.20 per share
management stability and insider confidenceDirect metric needs a verified mapping
grow revenue from rare disease therapiesRevenue: $0

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.8%Typical daily move · historical

Downside history

-87.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Rezolute, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk clinical-development story, not an established earnings compounder: the company is loss-making and reports no revenue or gross profit in the supplied evidence. The long-term thesis has weakened this month after recent performance fell to the lower half of its industry.

What's priced into Rezolute, Inc.

The evidence gives no usable valuation comparison or clear market-expectations measure, so whether the shares are cheap, fair, or expensive versus peers cannot be assessed. No fragility gates fired, but that does not resolve the uncertainty around the clinical programs or what expectations the market already reflects.

What the fundamentals likely do

Near term, earnings risk is elevated, with a recent miss and peers described as missing lately; recent results have also been mixed, with a beat in May and a miss in September. Over the multi-year view, progress depends on clinical and regulatory evidence: enrollment is complete for the 16-participant upLIFT study, while ersodetug’s sunRIZE study missed its primary endpoint despite the FDA encouraging a pre-BLA meeting, a step toward a possible application discussion.

What Rezolute, Inc. hinges on

The key near-term catalyst is the expected mid-December 2026 upLIFT topline result; the reported response among the first eight participants is encouraging but does not settle the outcome. The thesis also hinges on whether the ersodetug program finds a viable path after the missed primary endpoint, and whether sector conditions remain supportive as Healthcare bellwethers report.